You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NEI

    ABSTRACT Infection of the eye by Herpes Simplex Virus-1 (HSV-1) can result in Herpes Keratitis (HK), which is the leading cause of corneal blindness worldwide. Ocular herpes infections are often recurrent and culminate in progressive corneal scarring and loss of vision. The gold standard treatment is Acyclovir (ACV) that targets HSV-1 thymidine kinase (TK). Although ACV is highly effective against ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Next-generation precision medicine for targeting recombination-deficient cancers

    SBC: Recombination Therapeutics, LLC            Topic: O

    Precision medicine is a revolutionary therapeutic approach in which therapies are designed and selected based on genetic mutations present in certain cancers. For example, treating patients with BRCA-deficient cancers with a medicine that inhibits a particular DNA repair pathway can result in selective killing of these cancer cells. This approach is based upon the concept of synthetic lethality wh ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning

    SBC: Globin Solutions, Inc.            Topic: NIEHS

    Project Summary/AbstractCarbon monoxide (CO) poisoning remains a major cause of death and disability, affecting 50,000 persons a year in the U.S. alone. Victims removed from fires or rescued after exposure to car or home generator exhaust only have two options: 100% oxygen or transfer via ambulance or medical evacuation helicopter to a specialized facility with emergency hyperbaric oxygen chamber. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluation of a peptide that inhibitsthe activation of NOX2 and the generation of reactive oxygen species in protection against acute lung injury

    SBC: Peroxitech LLC            Topic: NHLBI

    SUMMARY: Acute lung injury (ALI) is a devastating complication of sepsis,viral and bacterial pneumonias, severe trauma with or without major blood loss, acid aspiration and other conditions that affect the lung either primarily or secondarily.This relatively common syndrome (~200,000 cases per yr in the US) currently has an overall mortality rate of ~40%. Lung inflammation associated with the prod ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Targeted delivery of amiodarone to the heart for atrial fibrillation utilizing novel cardiac targeting peptides

    SBC: Vivasc Therapeutics Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Atrial fibrillation (afib) is a common arrhythmia that affects more than 3 million people in the United States and contributes to substantial morbidity and mortality. The goals of medical therapy for all patients are to maintain sinus rhythm and to avoid the risk of complications (especially the increased risk of stroke) while minimizing symptoms to provide an acceptable q ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Advancing Small Molecule Read Through Compounds to Prevent and/or Treat Heritable Pulmonary Artery Hypertension

    SBC: Advent Therapeutics, Inc.            Topic: NHLBI

    Advent Therapeutics is a company that develops new therapies for neonatal, pediatric, and Orphan Drug “niche” markets to address serious unmet medical needs. Our team proposes early stage development of a new treatment for hereditable pulmonary arterial hypertension (hPAH), a rare, hereditary disorder that involves progressive elevation of pulmonary arterial pressures, right heart failure, and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a prototype software for automated PET/CT interpretation and reporting in thoracic cancer

    SBC: Quantitative Radiology Solutions LLC            Topic: 102

    Abstract. In cancer, body-wide FDG-PET/CT is a prime modality for diagnosis, staging, and treatment assessment. Despite its paramount importance to enable precision medicine in cancer, no method is currently available for automated disease burden estimation and standardized reporting on PET/CT images regionally and globally in anatomic organs and lymph node zones within a body region or body-wide. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling membrane protein structural analysis: Tools for capillary diffusion crystallization and remote in situ diffraction experiments

    SBC: Elk Valley Enterprises, Inc.            Topic: 400

    Project SummaryThis proposal is to develop an integrated capillary counter diffusion-based approach to in situ collection of macromolecule diffraction data. The method to be developed will enable both cryogenic and ambient temperature data collection, with the latter being critical to structure-based drug design. The approach is based on a capillary that is pre-mounted in a holder that facilitates ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. PROTACS Against Nef as a Functional Cure for HIV Infection

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    Abstract. Existing antiretroviral drugs do not clear HIV-1 latent reservoirs, underscoring the urgent need for new therapeutic strategies. The HIV-1 Nef accessory factor is an attractive target for drug development because of its critical roles in the HIV-1 life cycle and immune system escape. Our group has discovered novel small molecules that bind directly to Nef and block many of its functions, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Soft LXR Agonists for Idiopathic Pulmonary Fibrosis

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF) is a highly aggressive lung disease that develops almost exclusively in older individuals and has limited treatment options. An emerging paradigm in the field is that IPF results from chronic repetitive insults that exhaust the lung’s regenerative capacity, causing progressive tissue remodeling that leads to respiratory failure and death in the vast majority o ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government